Azelaic acid has sensitizing effect in the chemotherapeutic treatment of several melanoma cell lines

Pigment Cell Research

Volumn 9, Issue 6, 1996, Pages 317-325

  Rodriguez Vicente, J ^a   Vicente Ortega, V ^a,b   Canteras Jordana, ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Alkylating agents; Azelaic acid; B16F10; Drug modulator; In vitro cytotoxicity; Tyrosinase; Ultrastructure

Indexed keywords

4-HYDROXYANISOLE; ALKYLATING AGENT; ANISOLE DERIVATIVE; ANTINEOPLASTIC AGENT; AZELAIC ACID; DICARBOXYLIC ACID; LOMUSTINE; MELPHALAN; MEQUINOL; MONOPHENOL MONOOXYGENASE;

ANIMAL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL DIVISION; CELL VACUOLE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; SCANNING ELECTRON MICROSCOPY;

ANIMALS; ANISOLES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DIFFERENTIATION; CELL DIVISION; DICARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; LOMUSTINE; MELANOMA; MELPHALAN; MICE; MICROSCOPY, ELECTRON, SCANNING; MONOPHENOL MONOOXYGENASE; TUMOR CELLS, CULTURED; VACUOLES;

EID: 0030325055     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0749.1996.tb00124.x     Document Type: Article

References (60)

1. Alley, M.C., D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker, and M.R. Boyd (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48:589-601.
2. Belcher, H.J., C.G. Barsted, and C.M. Dawson (1990) 4-Hydroxyanisole: Human pharmacokinetics. Pigment Cell Res., 3:306-309.
3. Benathan, M., H. Alvero Jackson, A.M. Mooy, C. Scaletta, and E. Frenk (1992) Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells. Melanoma Res., 2:305-314.
4. Berger, W., L. Elbling, P.M. Minai, M. Vetterlein, R. Pirker, E.M. Kokoschka, and M. Micksche (1994) Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines. Int. J. Cancer 59:717-723.
5. Bertuzzi, A., A. Gandolfi, S. Salinari, G. Mingrone, E. Arcieri-Mastromatei, E. Finotti, and A.V. Greco (1991) Pharmacokinetic analysis of azelaic acid disodium salt. A proposed substrate for total parenteral nutrition. Clin. Pharmacokinet., 20:411-419.
6. Boring, C.C., T.S. Squires, and T. Tong (1992) Cancer statistics, 1992. CA Cancer J. Clin., 42:19-38.
7. Bramson, J. and L.C. Panasci (1993) Effect of ERCC-1 overexpression on sensitivity of Chinese hamster uvary cells to DNA-damaging agents. Cancer Res., 53:3237-3240.
8. Breathnach, A.S., E.J. Robins, Y. Bhasin, J. Ethridge, M. Nazzaro-Poro, S. Passi, and M. Picardo (1986) Observations on cell kinetics and viability of a human melanoma cell line exposed to azelaic acid. Histol. Histopathol., 1:235-240.
9. Breathnach, A.S., E.J. Robins, Y. Bhasin, J. Ethridge, M. Nazzaro-Poro and et al. (1987) Scanning electron microscopy of human and murine melanoma cells exposed to medium chain-length carboxylic acids in tissue culture. Histol. Histopathol., 2:291-297.
10. Breathnach, A.S., M. Nazzaro-Porro, S. Passi, and G. Zina (1989) Azelaic acid therapy in disorders of pigmentation. Clinics in Dermatology, 7:106-119.
11. Carmichael, J., W.G. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell (1987a) Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res., 47:936-942.
12. Carmichael, J., W.B. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell (1987b) Evaluation of tetrazolium-based semiautomated colorimetric assay: Assessment of radiosensitivity. Cancer Res., 47:943-946.
13. Chen, G. and D.J. Waxman (1994) Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem. Pharmacol., 47:1079-1087.
14. Fischel, J.L., P. Formento, P. Formento, M.C. Etienne, J. Gioanni, M. Frenay, P Deloffre, J.P Bizzari, and G. Milano (1990) In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother. Pharmacol., 25:337-341.
15. Fischel, J.L., V. Barbe, M. Berlion, P. Formento, J. Berrile, J.P. Bizzari, and G. Milano (1993) Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines. Eur. J. Cancer, 29A:2269-2273.
16. Fitton, A. and K.L. Goa (1991) Azelaic acid: A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs, 41:780-798.
17. Futscher, B.W., K. Campbell, and W.S. Dalton (1992) Collateral sensitivity to mitrosoureas in multidrug-resistant cells selected with verapamil. Cancer Res., 52:5013-5017.
18. Garcia Reverte, J.M., A. Bernabeu Esclapez, J. Muñoz Ramos, V. Vicente Ortega, and M. Canteras Jordana (1995) Effects of various antineoplastic agents on an established human melanoma cell line (G-361). Histol. Histopathol., 10:79-84.
19. Garrido Garcia, V.C., V. Vicente Ortega, A. Bernabeu Esclapez, J. Muñoz Ramos, and M. Canteras Jordana (1993) Estudio in vitro del 4-hidroxianisol (4-HA) y calor sobre dos líneas de melanomas murinos. Oncología, 16:109-117.
20. Gerson, S.L., S.J. Berger, M.E. Varnes, and C. Donovan (1994) Combined depletion of O6-alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer. Biochem. Pharmaeol., 48:543-548.
21. Grammatico, P., S. Scarpa, M. Picardo, K. Steindl, M. Nazzaro Porro, and G. Del Porto (1993) Karyotype modifications in human malignant melanoma cell cultures after treatment with azelaic acid. Mutat. Res., 300:119-123.
22. Hansson, J. and A.M. Fihctinger (1991) Comparative study of two human melanoma cell lines with different sensitivities to mustine and cisplatin. Eur. J. Cancer, 27:1039-1045.
23. Hoffman, D.W., P. Wiebkin, and L.P Rybak (1995) Inhibition of glutathione-related enzymes and cytotoxicity of ethacrinic acid and cyclosporine. Biochem. Pharmacol., 49:411-415.
24. Jang, A. and R.P. Hill (1991) Drug sensitivity and metastatic ability in B16 melanoma cells. Clin. Exp. Metastasis., 9:393-402.
25. Juliano, R.L. and V. Ling (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455:152-162.
26. Kameyama, K., M. Morita, K. Sugaya, S. Nishiyama, and V.J. Hearing (1992) Treatment of reticulate acropigmentation of Kitarnura with azelaic acid. An immunohistochemieal and electron microscopic study. J. Am. Acad. Dermatol., 26:817-820.
27. Koh, H.K. (1991) Cutaneous melanoma. N. Engl. J. Med., 326:171-182.
28. Leibl, H., G. Stingl, H. Pehamberger, H. Korshan, C. Konrad, and K. Wolff (1985) Inhibition of melanoma cells by azelaic acid. J. Invest. Dermatol., 85:471-422.
29. Lincke, C.R., A.M. van der Bliek, G.J. Schuurhuis, T. van der Velde-Koerts, J.J. Smit, and P. Borst (1990) Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdrl complementary DNA. Cancer Res., 50:1779-1785.
30. Lu, C., J.W. Rak, H. Kobayashi, and R.S. Kerbel (1993) Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. Cancer Res., 53:2708-2711.
31. McClean, S. and T.H. Bridget (1992) An overview of membrane, cytosolic, and nuclear proteins associated with the expression of resistance to multiple drugs in vitro. Biochim. Biophys. Acta, 1141:107-127.
32. Meijer, C., N.H. Mulder, H. Timmer-Bosscha, W.J. Sluiter, G.J. Meersma, and E.G.E. de Vries (1992) Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res., 52:6885-6889.
33. Miller, B.E., F.R. Miller, T. Machemer, and G.H. Heppner (1993) Melphalan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumour. Br. J. Cancer, 68:18-25.
34. Parsons, P.G. (1984) Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. Cancer Res., 44:2773-2778.
35. 18) dicarboxilic acids. Biochem. Pharmacol., 33:103-108.
36. Passi, S., M. Picardo, C. Zompetta, C. De Luca, A.S. Breathnach, and M. Nazzaro-Porro (1991a) The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic. Res. Commun., 15:17-28.
37. Passi, S., M. Picardo, C. De Luca, A.S. Breathnach, and M. Nazzaro Porro (1991b) Scavenging activity of azelaic acid on hydroxyl radicals "in vitro". Free Radic. Res. Commun., 11:329-338.
38. Persky, B., E.M. Peters, K.R. Gehlsen, J.M. Sorrention, F.L. Meysken, and M.J.C. Hendrix (1985) Scanning and transmission microscopic evaluation of human melanoma cells treated with Adriamycin and Actinomycin D. In: The integument. Scanning electron microscopy in skin biology. B. Forslind, C.W. Kischer, and G.M. Roomans, eds. AMF O'Hare, Illinois, pp. 983-995.
39. Phillips, M.F. and T.J. Mantle (1993) Inactivation of mouse liver glutathione S-transferase YfYf (Pi class) by ethacrynic acid and 5,5′-dithiobis-(2-nitrobenzoic acid). Biochem. J., 294:57-62.
40. Ploemen, J.H., B. Van Ommen, J.J. Bogaards, and P.J. Van Bladeren (1993) Ethacrynic acid and its glutathione conjugate as inhibitors of glutathione-S-transferases. Xenobiotica, 23:913-923.
41. Prezioso, J.A., G.B. Fitzgerald, and M.M. Wick (1992) Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-Dihydroxybenzylamine and melphalan. J. Invest. Dermatol., 99:289-293.
42. Revesz, L., M.R. Edgren, and A.A. Wainson (1994) Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys., 29:403-406.
43. Rodriguez Prieto, M.A., P. Manchado Lopez, I. Ruiz Gonzalez, and D. Suarez (1993) Treatment of lentigo maligna with azelaic acid. Int. J. Dermatol., 32:363-364.
44. Rofstad, E.K., A. Wahl, M.E. Hystad, J.M. Nesland, and T. Stokke (1991) Establishment in monolayer culture and characterization of four human melanoma cell lines. Virchows Archiv. B Cell. Pathol., 60:189-197.
45. Rustin, G.J., M.R. Stratford, A. Lamont, N. Bleehen, P.A. Philip, N. Howells, R.R. Wafta, and J.A. Slack (1992) Phase I study of intravenous 4-hydroxyanisole. Eur. J. Cancer 28a:1362-1364.
46. Schadendorff, D., M. Worm, B. Algermissen, and B.M. Czarnetzki (1994) Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitroi drug sensitivity. Cancer, 73:103-108.
47. Shcallreuter, K.U., F.K. Gleason, and J.M. Wood (1991) The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim. Biophics. Acta, 1054:14-20.
48. Schallreuter, K.U. and J.M. Wood (1990) New aspects in the pathophysiology of cutaneous melanoma: A review of the role of thioproteins and the effect of nitrosoureas. Melanoma Res., 1:159-169.
49. Smit, N.P., K. Peters, W. Menko, W. Westerhof, S. Pavel, and P.A. Riley (1992) Cytotoxicity of a selected series of substituted phenols towards cultured melanoma cells. Melanoma Res., 2:295-304.
50. Smith, P.K., R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Pujimoto, N.M. Goeke, B.J. Olson, and P.C. Klenk (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem., 150:76-85.
51. Stojcevic, L.L., A.H. Nias, and A.S. Breathnach (1995) Effect of azelaic acid on melanoma cell in culture. Exp. Dermatol., 4:79-81.
52. Tapiero, H., Y. Min-Biao, J. Catalin, M. Paraire, P. Deloffre, Y. Rostum, J.P. Bizzari, and T.D. Kenneth (1989) Cytotoxicity and DNA damaging effects of a new nitrosourea fotemustine, diethyl-1-1-(3-(20chloroethyl)-3-nitrosoureido)ehtylphosphonate'-S10036. Anticancer Res., 9:1617-1622.
53. Tidefelt, U., A. Elmhorm-Rosenborg, and C.H. Paul (1992) Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia. Cancer Res., 52:3281-3285.
54. Vecente, V., M. Gomez, S. Gomez, F. Calderon, M. Canteras, and A. Cremades (1987) Thermotherapy for Harding-Passey melanoma: Light and electron microscopic study. Histol. Histopathol., 2:369-381.
55. Vecente, V., M. Gomez, M.M. Ochotorena, A. Cremades, and M. Canteras (1990) Thermochemotherapy for B16 melanoma: Combination therapy of hyperthermia, melphalan and CCNU in mice. Pigment Cell Res., 3:1-7.
56. Vicente-Oretega, V., F. Martinez-Diaz, C. Carrascosa-Romero, G. Ortuno-Pacheco, M. Canteras-Jordana, and F. Calderon-Rubiales (1995) Abnormal melanosomes: Ultrastructural markers of melanocytic atypia. Ultrastructural Pathol., 19:119-128.
57. Wang, Y.Y., B.A. Teicher, T.C. Shea, S.A. Holden, K.W. Rosbe, A. al-Achi, and W.D. Henner (1989) Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance. Cancer Res., 49:6185-6192.
58. Winder, A.J. and H. Harris (1991) New assays for the tyrosine hydroxylase and dopa oxidase activities of tyrosinase. Eur. J. Biochem., 198:317-326.
59. Wu, L., A.M. Smythe, S.F. Stinson, L.A. Mullendore, A. Monks, D.A. Scudeiro, K.D. Puall, A.D. Koutsoukos, I.V. Rubinstein, M.R. Boyd, and R.H. Shoemaker (1992) Multidrug resistant phenotype of disease-oriented panels of human tumor cell lines for anticancer drug screening. Cancer Res., 53:3029-3034.
60. Yao, K.S., A.K. Godwin, R.F. Ozols, T.C. Hamilton, and P.J. Odwyer (1993) Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res., 53:3662-3666.